🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📣 Reminder Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Lactate Dehydrogenase Inhibitor for Primary Hyperoxaluria Treatment drughunters.com/3HjZ5sz Thursday, June 12th, 2025 8 AM PT / 11 AM ET / 5 PM CET Around 70% of patients with PH1–3 (primary

HBS1L: A Hot Synthetic Lethality Target with a Molecular Glue Degrader from Tango Therapeutics | drughunters.com/454RHv7 Two back-to-back Nature papers from AbbVie and the Broad Institute have spotlighted HBS1L/PELO as a compelling synthetic lethal partner in SKI-deficient

Atrasentan provides an intriguing story on the challenges in drug discovery for kidney diseases, the importance and interpretation of biomarkers, and the winding decades-long path drugs can take from initial therapeutic hypothesis to a suitable clinical indication. Full article:

The Sulfoximine Group: A Rising Star in Medicinal Chemistry | drughunters.com/3ZNex6M Ever thought about introducing sulfoximine moieties into your next drug design? Sulfoximines are versatile functional groups that can improve the physicochemical and ADME properties of drug

Crossfire’s Reversible, Macrocyclic BTK Inhibitor Displays Broad Preclinical Efficacy Against Drug-Resistant Mutants | drughunters.com/3FoHLSQ At the AACR Annual Meeting 2025 "Novel Antitumor Agents" symposium, Crossfire Oncology’s Jos de Man unveiled CFON-026, a reversible,

Simplifying Synthesis with Radical Cross-Coupling drughunters.com/45va3Wr Thursday, June 26th, 2025 8 AM PT / 11 AM ET / 5 PM CET Although radicals were historically perceived as highly reactive and somewhat uncontrollable species, radical chemistry has seen a dramatic

RIPTACs™ (regulated induced proximity targeting chimeras), first introduced by the Crews Lab, could provide safety margins similar to ADCs with the intracellular tumor-specific target protein acting similarly to tumor-specific antigens in ADCs. Read more:

Academic drug discovery thrives by tackling high-risk, long-term projects, and fundamental scientific questions. In her Flash Talk, Donna Huryn Professor of Chemistry at the University of Pittsburghand the University of Pennsylvania presents two innovative drug discovery

In our latest biopharma deal roundup, we highlight Novo Nordisk and Septerna’s new collaboration to develop oral GLP-1 receptor agonists, Sanofi’s acquisition of Vigil Neuroscience and its oral TREM2 agonist for Alzheimer’s disease, and Eli Lilly’s agreement to acquire non-opioid

Recently highlighted by Genentech at the AACR Annual Meeting 2025 “New Drugs on the Horizon” session, GDC-2992 is a CRBN-based heterobifunctional degrader and antagonist of AR, designed to tackle resistance in prostate cancer. Read more: drughunters.com/3HQXXNd

This article explores the biology of the TYK2 pathway, the rationale for targeting its pseudokinase domain, BMS’s discovery journey from phenotypic screening to clinical success, and how deucravacitinib is reshaping therapeutic strategies across inflammatory diseases. Read more:

A Brain-Penetrant GPR88 Agonist Probe for CNS Disorders This article traces the discovery, optimization, and in vivo validation of BI-9508 and its ongoing contribution to orphan GPCR research. Read more: drughunters.com/406pHnl

Key Clinical Updates from May 2025 Read more: drughunters.com/4dXoOTO

We provide a foundational understanding of the biology behind CDK-driven proliferation and explore the evolution from toxic pan-CDK inhibitors to today’s FDA-approved CDK4/6 drugs. Read more: drughunters.com/3ZupvhF

Precision therapies are changing the landscape of novel therapies for inherited kidney disease. In this Flash Talk, Renata Oballa, former Vice President of Research Operations and Vancouver Site Head at Chinook Therapeutics (a Novartis company), presents the discovery story of

Azetukalner (XEN1101) is a selective Kv7.2/Kv7.3 potassium channel opener that has shown efficacy in Ph. 2 trials of epilepsy and MDD (major depressive disorder), both of which have significant populations of treatment-refractory patients. Read it on Drug Hunter:

G12D is the most common mutation in RAS-driven cancers, and a surge of inhibitors and degraders of KRAS G12D have moved into clinical trials over the past two years, all looking to match the promising early data from Revolution Medicines’ RMC-9805. Whether or not AZD0022 will

📣 Reminder Simplifying Synthesis with Radical Cross-Coupling drughunters.com/3I2OPFl Thursday, June 26th, 2025 8 AM PT / 11 AM ET / 5 PM CET Historically, radical chemistry was overshadowed by two-electron chemistry due to the misconception that radical species are chaotic and

Since the approval of risdiplam, the first FDA-approved human RNA-targeting small molecule, a wave of oral small molecule splice modulators has emerged in preclinical and clinical development. This review focuses on diseases of the CNS in which small molecule splice modifiers

Do LRRK2 Heterobifunctional Degraders Mitigate “On-Target” Toxicity? | drughunters.com/3G1dny8 LRRK2 kinase inhibitors once promised to revolutionize Parkinson’s disease therapy—until preclinical lung toxicity, believed to be on-target, halted their progress. Heterobifunctional